©2022 Stanford Medicine
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status
Not Recruiting
Trial ID: NCT00986297
Purpose
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to
the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This phase I trial is studying the side effects and best dose of specialized
radiation therapy in treating patients with stage II, stage III, stage IV, or recurrent
non-small cell lung cancer and poor performance status.
Official Title
Phase 1 Study of Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-IV Non-Small Cell Lung Cancer and Poor Performance Status
Stanford Investigator(s)
Billy W Loo, Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Eligibility
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-small cell lung cancer
- Stage II-IV and/or recurrent disease
- No small cell histology
- Measurable or evaluable disease
- Tumor not amenable to surgical resection
- Tumor not eligible for stereotactic body radiation therapy
- No prior radiotherapy to the region of the study cancer that would result in overlap
of radiation therapy fields
PATIENT CHARACTERISTICS:
- Zubrod performance status 2-4
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must agree to use effective contraception
- Must complete all required pretreatment evaluations
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 1 week since prior chemotherapy or chemoradiation therapy
- No concurrent chemotherapy
- No other concurrent antineoplastic therapy (including standard-fractionated
radiotherapy to the chest, chemotherapy, biological therapy, vaccine therapy, and
surgery) 1 week before, during, and for 1 week after completion of study therapy
Intervention(s):
radiation: hypofractionated radiation therapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061